Investors: What’s The Real Deal With ChemoCentryx Inc. (NASDAQ: CCXI)

view original post

The trading price of ChemoCentryx Inc. (NASDAQ:CCXI) floating higher at last check on Monday, November 22, closing at $40.74, 2.88% higher than its previous close.

>> 7 Top Picks for the Post-Pandemic Economy <<

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $38.95 and $40.95. In examining the 52-week price action we see that the stock hit a 52-week high of $70.29 and a 52-week low of $9.53. Over the past month, the stock has gained 13.11% in value.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


ChemoCentryx Inc., whose market valuation is $2.76 billion at the time of this writing, is expected to release its quarterly earnings report Nov 08, 2021 – Nov 12, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.49 per share this quarter, however they have predicted annual earnings per share of -$1.96 for 2021 and -$2.15 for 2022. It means analysts are expecting annual earnings per share growth of -133.30% this year and -9.70% next year.

Analysts have forecast the company to bring in revenue of $8.66 million for the current quarter, with the likely lows of $2.5 million and highs of $34.04 million. The average estimate suggests sales will likely up by 70.30% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $35.42 million. The company’s revenue is forecast to drop by -45.40% over what it did in 2021.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of ChemoCentryx Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest CCXI has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CCXI a recommendation rating is 8. Out of them, 1 rate it a Hold, while 7 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged ChemoCentryx Inc. (CCXI) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

A quick review shows that CCXI’s price is currently 8.29% off the SMA20 and 37.35% off the SMA50. The RSI metric on the 14-day chart is currently showing 68.23, and weekly volatility stands at 4.27%. When measured over the past 30 days, the indicator reaches 5.12%. ChemoCentryx Inc. (NASDAQ:CCXI)’s beta value is currently sitting at 1.80, while the Average True Range indicator is currently displaying 1.97. With analysts defining $38.00-$110.00 as the low and high price targets, we arrive at a consensus price target of $71.38 for the trailing 12-month period. The current price is about 6.73% off the estimated low and -170.0% off the forecast high, based on this estimate. Investors will be thrilled if CCXI’s share price rises to $64.50, which is the median consensus price. At that level, CCXI’s share price would be -58.32% below current price.

To see how ChemoCentryx Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: CCXI stock’s performance was 2.88% at last check in today’s session, and -31.57% in the past year, while Biogen Inc. (BIIB) has been trading -0.09% in recent session and positioned 5.40% higher than it was a year ago. Another comparable company Johnson & Johnson (JNJ) saw its stock trading -0.60% lower in today’s session but was up 10.70% in a year. Furthermore, AbbVie Inc. (ABBV) showed an increase of 0.29% today while its price kept inclining at 16.62% over the past year. ChemoCentryx Inc. has a P/E ratio of 0, compared to Biogen Inc.’s 25.17 and Johnson & Johnson’s 24.35. Also during today’s trading, the S&P 500 Index has surged 0.71%, while the Dow Jones Industrial also saw a positive session, up 0.75% today.

An evaluation of the daily trading volume of ChemoCentryx Inc. (NASDAQ:CCXI) indicates that the 3-month average is 4.78 million. However, this figure has increased over the past 10 days to an average of 1.43 million.

Currently, records show that 69.89 million of the company’s shares remain outstanding. The insiders hold 0.60% of outstanding shares, whereas institutions hold 64.10%. The stats also highlight that short interest as of May 27, 2021, stood at 3.14 million shares, resulting in a short ratio of 0.53 at that time. From this, we can conclude that short interest is 4.50% of the company’s total outstanding shares. It is noteworthy that short shares in May were down slightly from the previous month’s figure, which was 3.53 million. However, since the stock’s price has seen -36.05% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.